drugset / Trial / NCT07186946

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

NCT07186946 ↗

Phase 1 Completed 16 enrolled Thryv Therapeutics, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your body is able to handle them) in healthy obese adults. This study will also look at how the drug moves through the body, is absorbed, distributed, metabolized and eliminated.

Timeline

Start
2025-09-15
Primary completion
2025-10-20
Completion
2025-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject THRV-1268 Unknown 100 mg Oral
Subject THRV-1268 Unknown 200 mg Oral

Indications